OBJECTIVES: To study the variations in self-reported health status of mainland Chinese patients with chronic hepatitis B (CHB) prior to initiating nucleos(t)ide analogues (NUC) treatment. METHODS: This study drew the baseline data of the EVOLVE study, an ongoing observational clinical study of NUCs for treating CHB patients with or without compensated cirrhosis in China. All patients underwent a basket of tests for liver functions and information on their clinical characteristics, life styles, health status (using the EQ-5D-3L questionnaire), and socio-economic status was obtained from medical records or personal interviews. Variations in self-reported health problems and global health were analyzed with logistic and linear regression models, respectively, to identify significant predictors using a stepwise selection method. RESULTS: Two thousand nine hundred and fifty-eight of the 3,434 NUC naïve CHB patients enrolled from 63 hospitals across China (mean age: 39.3 years; male: 73.1%; HBeAg positive: 61.1%; compensated cirrhosis: 20.4%) were included in this analysis. Among those, less than 2% reported problems in mobility, self-care, or usual activities; 15.8% and 16.5% reported pain/discomfort and anxiety/depression, respectively. The mean (standard deviation) global health score was 83.5 (13.3) on a 0 (worst) to 100 (best) scale. Independent predictors of reporting any of the EQ-5D health problems included female gender,  BMI 25-30 kg/m, presence of comorbidity (hypertension, hyperlipidemia, etc.), family history of liver cancer, albumin <28g/L, and HBeAg positive. Alcohol drinking, a diagnosis of CHB for >15 years, and presence of comorbidity were independent predictors of a lower global health score, with the effect size ranging between 1 and 4 points. CONCLUSIONS: CHB characteristics showed some association with patient-reported health problems, but their association with general health perception was minimal. The modest relationship between clinical and patient-reported outcomes measures supports the assessment of patient-reported outcomes in patients with CHB.